PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 181.51 Thousand CAD | -4.03% |
| 2022 | 189.13 Thousand CAD | 17.33% |
| 2021 | 161.2 Thousand CAD | -46.7% |
| 2020 | 302.45 Thousand CAD | -64.73% |
| 2019 | 857.63 Thousand CAD | -54.91% |
| 2018 | 1.9 Million CAD | -26.83% |
| 2017 | 2.59 Million CAD | 1154.77% |
| 2016 | 207.18 Thousand CAD | 159.79% |
| 2015 | 79.74 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 186.15 Thousand CAD | 2.56% |
| 2024 Q2 | 177.37 Thousand CAD | -4.72% |
| 2023 Q3 | 209.44 Thousand CAD | 9.04% |
| 2023 Q1 | 166.71 Thousand CAD | -11.85% |
| 2023 Q4 | 181.51 Thousand CAD | -13.34% |
| 2023 Q2 | 192.08 Thousand CAD | 15.22% |
| 2023 FY | 181.51 Thousand CAD | -4.03% |
| 2022 Q1 | 153.88 Thousand CAD | -4.54% |
| 2022 FY | 189.13 Thousand CAD | 17.33% |
| 2022 Q3 | 153.1 Thousand CAD | 9.32% |
| 2022 Q2 | 140.04 Thousand CAD | -8.99% |
| 2022 Q4 | 189.13 Thousand CAD | 23.53% |
| 2021 Q3 | 246.4 Thousand CAD | 119.97% |
| 2021 FY | 161.2 Thousand CAD | -46.7% |
| 2021 Q2 | 112.01 Thousand CAD | -49.54% |
| 2021 Q1 | 221.99 Thousand CAD | -26.6% |
| 2021 Q4 | 161.2 Thousand CAD | -34.58% |
| 2020 Q4 | 302.45 Thousand CAD | -44.08% |
| 2020 Q2 | 333.94 Thousand CAD | -49.63% |
| 2020 FY | 302.45 Thousand CAD | -64.73% |
| 2020 Q1 | 663.03 Thousand CAD | -22.69% |
| 2020 Q3 | 540.89 Thousand CAD | 61.97% |
| 2019 FY | 857.63 Thousand CAD | -54.91% |
| 2019 Q4 | 857.63 Thousand CAD | -37.15% |
| 2019 Q3 | 1.36 Million CAD | -22.13% |
| 2019 Q1 | 2.23 Million CAD | 17.27% |
| 2019 Q2 | 1.75 Million CAD | -21.44% |
| 2018 Q3 | 4.56 Million CAD | -39.33% |
| 2018 FY | 1.9 Million CAD | -26.83% |
| 2018 Q4 | 1.9 Million CAD | -58.37% |
| 2018 Q2 | 7.53 Million CAD | 210.12% |
| 2018 Q1 | 2.42 Million CAD | -6.59% |
| 2017 Q2 | 3.38 Million CAD | 887.51% |
| 2017 Q4 | 2.59 Million CAD | 26.26% |
| 2017 FY | 2.59 Million CAD | 1154.77% |
| 2017 Q1 | 342.42 Thousand CAD | 29.45% |
| 2017 Q3 | 2.05 Million CAD | -39.11% |
| 2016 Q3 | 111.32 Thousand CAD | -9.46% |
| 2016 Q2 | 122.95 Thousand CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | 207.18 Thousand CAD | 159.79% |
| 2016 Q4 | 264.53 Thousand CAD | 137.63% |
| 2015 FY | 79.74 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.28% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 90.731% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.861% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 48.67% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.753% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.656% |
| Qrons Inc. | 420.00 USD | -43116.667% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 67.125% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.35% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.395% |
| Skye Bioscience, Inc. | 11.94 Million USD | 98.48% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 62.229% |
| Rebus Holdings, Inc. | 5000.00 USD | -3530.2% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 73.598% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -7757.576% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.995% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 76.447% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.533% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 97.486% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -137.722% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.831% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 87.325% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -150.826% |
| Mesoblast Limited | 667.9 Million USD | 99.973% |
| Marizyme, Inc. | 22.01 Million USD | 99.176% |
| Genus plc | 1.02 Billion USD | 99.982% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 86.637% |
| Pharming Group N.V. | 462.85 Million USD | 99.961% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 94.521% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 63.628% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 71.051% |
| ContraFect Corporation | 20.67 Million USD | 99.122% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 53.503% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 52.506% |
| IMV Inc. | 31.33 Million USD | 99.421% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 95.622% |
| MultiCell Technologies, Inc. | 126.22 USD | -143704.468% |
| ONE Bio Corp. | 70.08 Million USD | 99.741% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 80.684% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.859% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 57.956% |
| Q BioMed Inc. | 3.51 Million USD | 94.837% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.484% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 30.53% |
| Biomind Labs Inc. | 73.81 Thousand USD | -145.885% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.959% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 87.472% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 93.391% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 93.027% |
| GB Sciences, Inc. | 103.44 Thousand USD | -75.47% |
| Alpha Cognition Inc. | 2.45 Million USD | 92.598% |
| HST Global, Inc. | 1526.00 USD | -11794.495% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 81.628% |
| Halberd Corporation | 10.13 Thousand USD | -1691.63% |
| Enzolytics Inc. | 361.7 Million USD | 99.95% |
| Agentix Corp. | 261.39 Thousand USD | 30.56% |
| Resverlogix Corp. | 8.11 Million USD | 97.763% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 90.334% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.996% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.619% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 71.624% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -696.76% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 97.972% |
| AVAX Technologies, Inc. | 7.37 Million USD | 97.54% |
| Zenith Capital Corp. | 7410.00 USD | -2349.528% |
| Ember Therapeutics, Inc. | 184.00 USD | -98546.739% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 43.596% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 30.553% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 80.44% |
| Kadimastem Ltd | 2.3 Million USD | 92.122% |
| Helix BioMedix, Inc. | 3.02 Million USD | 94.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -217.914% |
| LadRx Corporation | 2.3 Million USD | 92.135% |
| Cell Source, Inc. | 195.17 Thousand USD | 7.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 48.67% |
| NovAccess Global Inc. | 62.24 Thousand USD | -191.592% |
| Affymax, Inc. | 7.44 Million USD | 97.561% |
| Itoco Inc. | 1.4 Million USD | 87.036% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -89.751% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -71.236% |
| Mobile Lads Corp. | 52.00 USD | -348957.692% |
| CytoDyn Inc. | 11.13 Million USD | 98.37% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -26.955% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -915.157% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 52.912% |
| SYBLEU INC | 330.46 Thousand USD | 45.075% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 55.667% |
| International Stem Cell Corporation | 5.39 Million USD | 96.632% |
| Bioxytran, Inc. | 137.63 Thousand USD | -31.875% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.79% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.905% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -129.759% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 79.008% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 97.585% |
| Neutra Corp. | 2851.00 USD | -6266.538% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.44% |
| PureTech Health plc | 693.97 Million USD | 99.974% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 97.751% |
| IXICO plc | 15.84 Million USD | 98.854% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 97.808% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.824% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.946% |